BONE CANCER

What is bone cancer?

Bone cancer is a malignant growth that develops in bone tissue (primary bone cancer) as opposed to occurring in bone due to spread from another organ (metastatic bone disease). Primary bone cancers are uncommon and represent a number of histologic types each with different patterns of expansion, affected age group, and therapy strategies. They are distinguished from bone metastases, which are much more frequent and occur as a consequence of tumors within other organs spreading into the bone.

Statistics and Extent

• Primary bone cancers are uncommon. They occur about 1 new case per 100,000 individuals in the United States each year. Only a few thousand new cases occur annually, according to estimates. Worldwide, rates range from 1 to 3 cases per million individuals per year for some types, varying with age group and area. Even though they are rare, bone cancers are substantial because of their dangerous nature and intensive therapy needed.

The bone cells Bone is a framework of soft supporting tissue called connective tissue containing calcium which hardens the bones. There are 3 main types bone cells which work together to maintain the shape, strength and health of the bones. These are the:

• osteoblasts
• osteoclasts
• osteocytes

If a bone gets damaged, the osteoblasts make new bone to repair the damage.

The osteoclasts break down any extra bone framework that the osteoblasts make and reshape the bone. When bone forms, osteoblasts are trapped within it and become part of the framework. They are then called osteocytes and maintain the bone structure.

• Inside some of the bones of the body is a space that is filled with bone marrow . Blood cells are made in the bone marrow. All blood cells develop from STEM CELLS  which are found in the bone marrow.

Where does bone cancer start?

• Primary bone cancer starts in cells of the bones. Doctors sometimes use the term bone sarcoma when they talk about primary bone cancer. Sarcomas are cancers that start in any connective tissue in the body. This includes the bones but also:
• muscles
• tendons
• blood vessels
• fatty tissues

Types of Primary Bone Cancer -

There are several different types of primary bone cancer that start in bone cells that have become cancerous.

Chondrosarcoma - Chondrosarcoma is the most common type of primary bone cancer. It develops from cartilage cells within the bone and most often affects adults aged 30–60.

Osteosarcoma - Osteosarcoma is the second most common primary bone cancer. It develops from bone-forming cells.

It can occur at any age but is most common in:

• Children
• Teenagers and young adults
• Older adults (70s–80s)

Ewing Sarcoma - Ewing sarcoma most often affects children and adolescents, but adults can develop it as well. It can occur in bone or soft tissues such as muscle, fat, blood vessels, nerves, tendons, ligaments, deep skin tissues, and tissues around joints. Soft tissue Ewing sarcoma is treated similarly to Ewing bone tumors.

Round Cell Sarcoma - Round cell sarcoma is closely related to Ewing sarcoma and is often defined by specific gene mutations. Treatment is usually the same as for Ewing sarcoma.

Other Unusual Types -

• Undifferentiated pleomorphic sarcoma of bone
• Fibrosarcoma of bone
• Leiomyosarcoma of bone

Rarer Types -

• Spindle cell sarcoma
• Chordoma

Location

It varies based on the bone cancer type:

Osteosarcoma – Commonly in the metaphysis of long bones like the distal femur, proximal tibia, or proximal humerus

Ewing sarcoma – Usually in the shaft (diaphysis) of long bones, pelvis, ribs, or vertebra

Chondrosarcoma – Most common in the pelvis, femur, humerus, or ribs

Spindle cell sarcoma – Usually soft tissues (can occur anywhere in the body)

Chordoma – Along the spine or skull base

Staging and grading for bone cancer

Staging means how big the cancer is and whether it has spread. Grading means how abnormal the cancer cells look under a microscope. This helps work out the treatment ONE need for THEIR bone cancer.

Stages

Staging of bone cancer identifies how widespread the disease is. The TNM system is employed:

• T – Size of the tumor and degree of spread within the bone or to nearby tissues.
• N – Involvement of lymph nodes.
• M – Evidence of metastasis (spreading to distant organs, most often the lungs or other bones).
• Sarcoma staging systems also apply grade of the tumor to estimate aggressiveness.In the TNM system, bone cancer cells are graded from GX to G3:
• grade X (GX) means the grade cannot be assessed
• grade 1 (G1) means the cells look similar to normal bone cells (low grade)
• grade 2 (G2) means the cells look quite different to normal bone cells (high grade)
• grade 3 (G3) means the cells look very different to normal bone cells (high grade)
• All Ewing sarcomas are high grade (G3).Another system accompanying the TNM system is the number staging system, which is as follows –

The tumour, node and metastasis results are put together with the grading to give the number stage. The following is a summary of the staging for bone cancer. There is no number staging for bone cancer that starts in the back (spine) and pelvis.

• Stage 1A - The cancer is 8 cm or less across. It has not spread to the lymph nodes or other parts of the body. The cancer is low grade or the grade can't be assessed.
• Stage 1B - The cancer is more than 8 cm across, or is in more than one place in the same bone. It has not spread to the lymph nodes or other parts of the body. The cancer is low grade or the grade can't be assessed.
• Stage 2A - The cancer is 8 cm or less across. It has not spread to the lymph nodes or other parts of the body. The cancer is high grade.
• Stage 2B - The cancer is more than 8 cm across. It has not spread to the lymph nodes or other parts of the body. The cancer is high grade.
• Stage 3 - The cancer is in more than one place in the same bone. It has not spread to the lymph nodes or other parts of the body. The cancer is high grade.
• Stage 4A - The cancer is any grade and is either:
• any size
• in more than one place in the same bone
• There are no cancer cells in the lymph nodes and it has only spread to the lung.
• Stage 4B - This means the cancer has spread to the lymph nodes or to parts of the body such as the liver, other bones or the brain.

Common symptoms

• Persistent bone pain — often worse at night, at rest, or with activity; may be felt away from the tumor (referred pain).
• Swelling or lump over a bone or joint (not always visible).
• Difficulty moving or limping due to pain or stiffness.

Less common symptoms

• Weak bone fractures from minor or no injury (pathological fracture).
• Fatigue, fever or sweats, and unintentional weight loss.

Risk Factors and Causes

The specific reason for most cancers of the bone is not known, but the following factors raise the risk:

• Inherited syndromes – Li-Fraumeni syndrome (TP53 mutation), retinoblastoma syndrome (RB1 mutation).What is the Li-Fraumeni Syndrome? A rare inherited (autosomal dominant) condition caused by a TP53 gene mutation that gives a very high lifetime risk of multiple early cancers — especially breast cancer, soft-tissue and bone sarcomas, brain tumors, and adrenocortical cancer. Diagnosis is by genetic testing, and management involves lifelong intensive screening (often annual whole-body MRI) because of radiation sensitivity and risk of second cancers.
• A history of previous radiation therapy to the bones – Especially therapeutic radiation in childhood or adolescence.
• Paget's disease of the bone – Osteosarcoma risk increases with this disorder in older adults.
• Dysplasias and some benign bone lesions.How cancer spreads
• Primary cancer origin - Cancer begins at a specific site called the primary tumour. If some cancer cells break away, they can travel to other parts of the body and form new tumours called secondary cancers or metastases. Even after spreading, cancer is named after where it first started.
• Main routes of spreadCancer commonly spreads through two systems:
• Bloodstream
• Lymphatic system
• Detachment and movement - For spread to occur, cancer cells must detach from the original tumour. They often move more easily than normal cells because they do not stick tightly together and may produce substances that help them invade nearby tissues.
• Spread through the bloodstream - Cancer cells can enter small blood vessels and circulate in the blood.
• Many circulating cancer cells are destroyed by immune cells or damaged by blood flow.
• Some survive, attach to blood vessel walls, move into nearby tissues, and multiply to form new tumours if conditions are suitable.
• Cancer cells may cluster with platelets, which can help protect them and support spread.
• Spread through the lymphatic system -
• The lymphatic system drains fluid and helps fight infection.Cancer cells can enter lymph vessels near the tumour and travel to lymph nodes.Some cells die in lymph nodes, but others survive and grow, leading to lymph node involvement.
• MicrometastasesSometimes cancer spreads in very tiny amounts that cannot be detected by scans. These small areas are called micrometastases and may only be suspected based on risk factors.

Prevention

There are no definite ways to avoid most primary bone cancers. However:

• Minimize unnecessary high-dose radiation exposure.
• Genetic counselling for individuals with hereditary cancer syndromes.
• Ongoing monitoring for high-risk patients.

Diagnosis

Diagnosis is done by a combination of imaging and biopsy:

• X-rays – First test, revealing bone destruction or abnormal bone growth.
• MRI – Ideal for evaluating tumor size within the bone and soft tissue.
• CT scan – Critical to identify lung metastases.
• Bone scan / PET-CT – Assess spread to other bones.
• Biopsy – Establishes diagnosis, establishes type and grade of tumor.

Treatment of bone cancer (complete overview)

Treatment depends on the cancer type, stage, location, spread, and overall health, and usually combines several methods.

1. **Surgery (primary treatment)**The main goal is complete tumour removal with a margin of healthy tissue. Most patients have limb-sparing surgery with reconstruction using a prosthesis or bone graft. Surgery may also be used to stabilise weakened bones or repair fractures.
2. ChemotherapyAnti-cancer drugs destroy cancer cells and are commonly used for aggressive bone cancers. It may be given before surgery to shrink the tumour or after surgery to reduce recurrence risk. It can also treat cancer that has spread**.**
3. RadiotherapyHigh-energy radiation kills cancer cells. It is used when surgery is not possible, to shrink tumours before surgery, or to control remaining cancer after treatment.

Additional and supportive treatments (especially for advanced or secondary bone cancer)

• Targeted therapy (e.g., monoclonal antibodies like denosumab) to slow bone destruction and reduce fractures.
• Bisphosphonates to strengthen bones, reduce pain, and lower calcium levels.
• Hormone therapy for cancers that depend on hormones (such as breast or prostate cancers that spread to bone).
• Radioisotope therapy (e.g., radium-based treatment) delivers radiation from inside the body to bone metastases.
• Radiofrequency ablation (RFA) uses heat to destroy tumour tissue.
• Bone cement injection to stabilise painful or weakened bones.
• Palliative treatments to relieve pain, improve mobility, and maintain quality of life.

Overall approach - Management is multidisciplinary and often combines tumour removal, cancer-killing therapies, and bone-strengthening treatments, followed by long-term monitoring for recurrence or complications.

Side Effects and Maintenance

Treatment may have short- and long-term consequences:

Short-term – Fatigue, nausea and vomiting, hair loss, skin irritation or sun sensitivity, mouth sores and difficulty eating, loss of appetite or taste changes, constipation or diarrhea, low blood counts (anemia, infection risk, bruising/bleeding), weakened immune system, bladder or kidney irritation.

Long-term – Peripheral neuropathy (numbness or tingling in hands/feet), fertility problems or early menopause, memory and concentration difficulties (“chemo brain”), possible lasting organ effects depending on drugs used.

Follow-up care – Ongoing imaging and monitoring, management of side effects, physical rehabilitation to restore strength and movement, psychological support, and long-term surveillance for complications or recurrence.

FAQs

Q: Is bone cancer the same as bone metastasis?

A: No. Primary bone cancer begins in bone cells; metastases originate from cancers elsewhere.

Q: What are the chances of cure?

A: Depending on type, stage, and treatment; localized cases usually have favorable survival rates.

Q: Are there screening tests?

A: No standard screening; high-risk persons can be followed.

Q: Will diet prevent bone cancer?

A: No dietary prevention has been proven.

Q: What is malignant fibrous histiocytoma of bone?

A Malignant fibrous histiocytoma of bone is a rare type of cancer which occurs in adults. The most common sites of MFH are the legs and arms. Treatment is often similar to that given for osteosarcoma. MFH can also arise in the soft tissues.

Q: How soon after treatment will I feel better?

Pain related to bone cancers often improves soon after treatment starts. But the treatments can cause some side effects and require recovery. It may take up to six months of rehabilitation and physical therapy to get used to a prosthesis. With limb-sparing surgery, it may take up to a year to feel completely comfortable with the changes in your bones. Ultimately, your recovery time depends on the cancer type, stage and the combination of treatments you need. Your healthcare provider will let you know what to expect so you can decide which treatments work best for you.

Q: What is the survival rate for bone cancer?

Though bone cancers can be fatal, many people make a full recovery. The five-year relative survival rate for bone cancer is 68.2%. Those with lower-stage bone cancers have a better chance of a full recovery. For people with higher-stage bone cancers, where it’s already spread, the chances of the cancer coming back increase. Keep in mind that survival rates are only estimates based on people who’ve had bone cancers in the past. They can’t predict how long you’ll live or what to expect in your unique situation.

Results and Statistics

Bone cancer ASRs (1993–2017) ranged from 0.53 to 2.72 for females (China: Yunmeng County, 2.72 [2.16–3.28]) and 0.90–4.28 for males (China: Xiangfu District, 4.28 [3.25–5.31], p < 0.0001), with minimal rates near zero like Brazil: Jau and USA: Hawaii Chinese.

Mortality rates (1980–2021) peaked in Eastern Europe and Central Asia, with male rates up to 2.90 (Romania, 2.90 [1.89–3.90], 1980) and female rates up to 2.34 (Greece, 2.34 [2.11–2.58], 1980), while high-income regions like Western Europe declined to 0.84 (males, 0.84 [0.76–0.90], 2021). By 2021, Upper Middle-Income countries (1.26 [0.85–1.62] for males) and Basic Health Systems (1.27 [0.85–1.59] for males) showed rising mortality, surpassing Advanced Health Systems (0.76 [0.71–0.81] for males), reflecting healthcare disparities.

Thailand (males, 2.06 [1.18–3.01], 2021) and China saw increasing rates, unlike stable low rates in the USA (males, 0.71 [0.67–0.74], 2021).

Citations and sources

1.National Cancer Institute (NCI)

2.Mayo Clinic

3.Cleveland Clinic

4.American Cancer Society (ACS)

5.World Health Organisation (WHO)- Cancer prevention programs